Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions
Isabella C. Glitza, Keiran S.M. Smalley, Priscilla K. Brastianos, Michael A. Davies, Ian E. McCutcheon, James K. Liu, Kamran A. Ahmed, John A. Arrington, Brittany Evernden, Inna Smalley, Zeynep Eroglu, Nikhil I. Khushalani, Kim Margolin, Harriet M. Kluger, Michael B. Atkins, Hussein A. Tawbi, Adrienne Boire, Peter Forsyth
Abstract
In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System Metastases in Tampa, Florida. The meeting included investigators from multiple academic centers and disciplines. A consensus summary of the progress and challenges in melanoma parenchymal brain metastases was published (Eroglu et al., Pigment Cell & Melanoma Research, 2019, 32, 458). Here, we will describe the current state of basic, translational, clinical research, and therapeutic management, for melanoma patients with leptomeningeal disease. We also outline key challenges and barriers to be overcome to make progress in this deadly disease.